Background: To determine which short-term changes on clinical scales including the Expanded Disability Status Scale (EDSS), Timed 25-Foot Walk (T25FW), 9-Hole Peg test (9HPT) and Guy’s Neurological Disability Scale (GNDS) are most predictive of long-term outcome of disability as rated by the EDSS in progressive multiple sclerosis (MS).
Methods: From a longitudinal database, all progressive patients, both primary (PP) and secondary (SP), were selected on the basis of at least two complete examinations being available within a time interval of 1–2 years (short-term change). All patients who fulfilled the selection criteria were invited for a third visit after an interval of at least 3 years (long-term outcome). We used ordinal logistic regression to see which early changes were most predictive of the long-term EDSS.
Results: 181 patients fulfilled the selection criteria. Early change on EDSS and T25FW were the best predictors of long-term EDSS; both were significant predictors in a ‘single predictor’ model. Early EDSS change was a slightly stronger single predictor (R2 0.38, Wald χ2 42.65, p < 0.001) compared with early T25FW change (R2 0.27, Wald χ2 12.35, p < 0.001). Adding early T25FW change to early EDSS change in a ‘combined predictor’ model improved prediction (p = 0.036).
Conclusion: Both early change on EDSS and T25FW predict long-term EDSS with comparable strength. Early change on T25FW adds significant independent information and improves the prediction model with early EDSS change only. Therefore we support the use of early T25FW examinations in future clinical trials in progressive MS.
KremenchutzkyMRiceGPBaskervilleJWingerchukDMEbersGC. The natural history of multiple sclerosis: a geographically based study 9: observations on the progressive phase of the disease. Brain2006; 129: 584–584.
4.
RudickRAKapposL. Measuring disability in relapsing-remitting MS. Neurology2010; 75: 296–297.
5.
KurtzkeJF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology1983; 33: 1444–1452.
6.
CutterGRBaierMLRudickRA. Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain1999; 122: 871–882.
7.
SharrackBHughesRA. The Guy’s Neurological Disability Scale (GNDS): a new disability measure for multiple sclerosis. Mult Scler1999; 5: 223–223.
8.
HobartJFreemanJThompsonA. Kurtzke scales revisited: the application of psychometric methods to clinical intuition. Brain2000; 123: 1027–1027.
9.
LublinFDReingoldSC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology1996; 46: 907–907.
10.
PoserCMPatyDWScheinbergL. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol1983; 13: 227–227.
11.
PolmanCHReingoldSCEdanG. Diagnostic criteria for multiple sclerosis: 2005 revisions to the ‘McDonald Criteria’. Ann Neurol2005; 58: 840–840.
12.
Lechner-ScottJKapposLHofmanM. Can the Expanded Disability Status Scale be assessed by telephone?Mult Scler2003; 9: 154–154.
13.
CottrellDAKremenchutzkyMRiceGP. The natural history of multiple sclerosis: a geographically based study. 5. The clinical features and natural history of primary progressive multiple sclerosis. Brain1999; 122: 625–625.
14.
CohenJACutterGRFischerJS. Use of the multiple sclerosis functional composite as an outcome measure in a phase 3 clinical trial. Arch Neurol2001; 58: 961–961.
15.
SolariARadiceDManneschiLMottiLMontanariE. The multiple sclerosis functional composite: different practice effects in the three test components. J Neurol Sci2005; 228: 71–71.
